Fig. 1.

This figure outlines the design of the study. Comparison (->) or correlation (<->) of the relative reduction of KIT D816V positive single-cell-derived myeloid progenitor cells (CFU-GM colonies) between: prior to treatment versus midostaurin in vitro (1a) or avapritinib in vitro (1b), midostaurin in vitro versus avapritinib in vitro (1c), prior to treatment versus midostaurin in vivo (2a), midostaurin in vivo versus midostaurin in vitro (2b), and patients profile (including clinical, laboratory, histological, and molecular data) and established response assessment [3, 41] (after six month midostaurin treatment) versus midostaurin in vitro (3a) and in vivo (3b) assay. CFU-GM granulocyte-macrophage colony-forming-unit